News - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

490 to 514 of 516 results

Johnson & Johnson to take $500-$600 million charge as Cordis drops Cypher heart stents

17-06-2011

US health care giant Johnson & Johnson (NYSE: JNJ), which has suffered a steady stream of bad news relating…

Cardio-vascularFinancialJohnson & JohnsonPharmaceutical

US FDA curbs use of high-dose simvastatin, citing increased risk of muscle injury

09-06-2011

The US Food and Drug Administration yesterday announced safety label changes for the cholesterol-lowering…

Abbott LaboratoriesCardio-vascularMerck & CoNorth AmericaPharmaceuticalRegulationSimcorSimvastatinZocor

Sanofi presents benefits of semuloparin; Zaltrap improves colorectal cancer survival

07-06-2011

French drug major Sanofi (Euronext: SAN) announced results at the American Society of Clinical Oncology…

Cardio-vascularGastro-intestinalsOncologyPharmaceuticalRegeneronResearchSanofisemuloparinZaltrap

US FDA says use of ARBs for hypertension does not increase risk of cancer

03-06-2011

The US Food and Drug Administration stated yesterday that a group of drugs used to control high blood…

Cardio-vascularNorth AmericaPharmaceuticalRegulation

Health Canada OKs AstraZeneca’s Brilinta and new use for Merck’s Gardasil

02-06-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says that Health Canada has approved Brilinta (ticagrelor…

AstraZenecaBrilintaCardio-vascularGardasilMerck & CoNorth AmericaOncologyPharmaceuticalRegulation

Roche joins forces with ChemRar on developing new antithrombotic drug for Russia

30-05-2011

Swiss pharmaceutical major Roche (ROG: SIX) and Russian TeaReks company, a subsidiary of ChemRar, Roche's…

Cardio-vascularChemRar Hi-TechEuropeLicensingPharmaceuticalRocheTeaReks

Efficacy and stroke concerns halt trial of Abbott cholesterol drug Niaspan combo

27-05-2011

US health care major Abbott Laboratories (NYSE ABT) has halted its AIM-HIGH clinical trial of Niaspan…

Abbott LaboratoriesCardio-vascularNiaspanPharmaceuticalResearchSimvastatin

Synovate Healthcare launches Hyperlipidemia Monitor in Asia-Pacific

27-05-2011

Synovate Healthcare, the health care specialist unit of market research firm Synovate, says it has launched…

Asia-PacificCardio-vascularHealthcarePharmaceutical

US Senators accuse Sanofi over lobbying FDA on generic Lovenox

26-05-2011

US Senate Finance Committee Chairman Max Baucus (Democrat, Montana) and senior Committee Member Chuck…

Cardio-vascularGenericsLovenoxNorth AmericaPharmaceuticalRegulationSanofi

UK’s NICE recommends naftidrofuryl oxalate for symptoms of peripheral arterial disease

26-05-2011

The National Institute for Health and Clinical Excellence (NICE) has today issued final guidance recommending…

Cardio-vascularEuropeMerck SerononaftidrofurylPharmaceuticalPraxilenePricingRegulation

Pfizer’s Inspra shown to reduce AF in Ph IIIb trial

24-05-2011

Global drugs behemoth Pfizer (NYSE: PFE) has reported results from a sub-analysis of the Phase IIIb EMPHASIS-HF…

Cardio-vascularInspraPfizerPharmaceuticalResearch

Pfizer and Bristol-Myers get first approval for blood thinner Eliquis, in EU

23-05-2011

Following a positive recommendation from its drug advisory body (The Pharma Letter March 21), the European…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalRegulation

FDA advisory panel backs continued use of Abbott’s Trilipix with statins

20-05-2011

The US Food and Drug Administration’s Endocrinologic and Metabolic Drugs Advisory Committee to review…

Abbott LaboratoriesCardio-vascularNorth AmericaPharmaceuticalRegulationTrilipix

Bayer/Ortho-McNeil’s VTE drug Xarelto will earn peak-year sales of $500 million to $1 billion

17-05-2011

Following its expected launch in the USA in 2012 for venous thromboembolism (VTE) prophylaxis in medically…

BayerCardio-vascularEliquisJohnson & JohnsonMarkets & MarketingOrtho-McNeilPharmaceuticalXarelto

AstraZeneca achieves three significant milestones for blood thinner Brilique

10-05-2011

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday announced three items of news regarding its…

AstraZenecaBrilintaBriliqueCardio-vascularEuropePharmaceuticalPricingRegulationResearch

Recordati 1st-qtr 2011 sales up 6.4%, despite generic lercandipine, pivastatin debut

10-05-2011

talian drugmaker Recordati SpA (REC: MI) has presented results for the first quarter of 2011 and its…

Cardio-vascularEuropeFinanciallercandipineMarkets & MarketingPharmaceuticalPitavastatinRecordati

Actelion to appeal final jury verdict in Asahi Kasei litigation in US Court

04-05-2011

Switzerland-based Actelion (SIX: ATLN) today commented on the verdict issued with regard to Japan’s…

ActelionAsahi KaseiBiotechnologyCardio-vascularCoTherixfasudilLegalLicensing

Novartis gains EU approval for combo drug Rasilamlo to treat high BP

29-04-2011

Swiss drug major Novartis (NOVN: VX) says that Rasilamlo, a single-pill combination of aliskiren and…

Cardio-vascularEuropeNovartisPharmaceuticalRasilamloRegulation

Karo Bio and Alkem Labs collaborate to develop eprotirome

28-04-2011

Sweden’s Karo Bio AB (STO KARO) and Indian drugmaker Alkem Laboratories have entered into a collaboration…

Alkem LaboratoriesAsia-PacificCardio-vasculareprotiromeKaro BioLicensingPharmaceuticalResearchRest of the World

UK NICE gives final yes for Amgen’s Nplate but no for PharmaMar’s Yondelis

27-04-2011

There was mixed news this morning from the UK’s drug rationing body the National Institute for Health…

AmgenBiotechnologyCardio-vascularEuropeNplateOncologyPharmaceuticalPharmaMarRegulationYondelisZeltia

490 to 514 of 516 results

Back to top